Population Pharmacokinetics of Osimertinib in Patients With Non‐Small Cell Lung Cancer
Pharmacology Research & Perspectives · 2025
DOI: 10.1002/prp2.70098 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Martin Johnson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Science, R&D, AstraZeneca, Cambridge, UK. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Aniline Compounds, Acrylamides, Lung Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Population pharmacokinetics (popPK) modeling for osimertinib, a third‐generation, irreversible, oral epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR‐TKI sensitizing mutations and EGFR T790M, was previously reported utilizing AURA and AURA2 data (advanced non‐small cell lung cancer [NSCLC]). We report updated popPK modeling incorporating AURA3 and FLAURA data (advanced NSCLC); model validation used ADAURA data (resected stage IB–IIIA NSCLC). Updated popPK analyses were based on patients from AURA ( n = 599), AURA2 ( n = 210), AURA3 ( n = 277), and FLAURA ( n = 278) using a linear one‐compartmental disposition model for osimertinib and its metabolite, AZ5104, with first‐order oral absorption. A full covariate model, using Monte Carlo simulations, was developed to assess the effects of covariates on osimertinib and AZ5104 clearance. External validation was conducted using ADAURA study data ( n = 325). In the final popPK model, the apparent clearance and volume of distribution of osimertinib (14.3 L/h; 918 L) and AZ5104 (31.3 L/h; 143 L) were comparable to previous analyses. Albumin levels and body weight influenced osimertinib PK, but the effects were not considered clinically meaningful; other covariates had no impact on PK. Goodness‐of‐fit plots indicated that the model adequately described all data. Visual predictive checks showed that the final model validated osimertinib steady‐state PK for adjuvant treatment. PopPK modeling indicated that osimertinib dose adjustment is not required for patients' age, sex, body weight, race, smoking status, or line of therapy, confirming that a fixed 80 mg once‐daily dose is optimal for osimertinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Science, R&D, AstraZeneca, Cambridge, UK.
- Certara, Radnor, Pennsylvania, USA.
- IntiQuan GmbH, Basel, Switzerland.
- Oncology Biometrics, AstraZeneca, Cambridge, UK.
- Global Medicines Development, AstraZeneca, Cambridge, UK.
- Clinical Pharmacology and Safety Science, R&D, AstraZeneca, Waltham, Massachusetts, USA.
ORCID-Profile: Mikael Sunnaker, Karthick Vishwanathan
Förderung
- AstraZeneca
Zitieren
APA
Johnson, M., Lin, Y. W., Schmidt, H., Sunnaker, M., Van Maanen, E., Huang, X., Rukazenkov, Y., Tomkinson, H., & Vishwanathan, K. (2025). Population Pharmacokinetics of Osimertinib in Patients With Non‐Small Cell Lung Cancer. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70098
Vancouver
Johnson M, Lin YW, Schmidt H, Sunnaker M, Van Maanen E, Huang X, et al. Population Pharmacokinetics of Osimertinib in Patients With Non‐Small Cell Lung Cancer. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70098
BibTeX
@article{Johnson2025,
author = {Johnson, Martin and Lin, Yu-Wei and Schmidt, Henning and Sunnaker, Mikael and Van Maanen, Eline and Huang, Xiangning and Rukazenkov, Yuri and Tomkinson, Helen and Vishwanathan, Karthick},
title = {Population Pharmacokinetics of Osimertinib in Patients With Non‐Small Cell Lung Cancer},
journal = {Pharmacology Research & Perspectives},
year = {2025},
doi = {10.1002/prp2.70098}
}
EUVIMED